EPISODE · Dec 13, 2022 · 14 MIN
ASH Highlights - ALPINE Trial Shows Improved Efficacy and Safety Profile of Zanubrutinib vs Ibrutinib in CLL
from IMPACT Medicom · host IMPACT Medicom
Live From ASH, New Orleans:In this episode, Dr. Jennifer Brown discusses results of the phase 3 ALPINE trial, presented as a late breaking abstract at the American Society of Hematology (ASH) meeting 2022 in New Orleans, LA. Note: The ALPINE trial was published today in the New England Journal of Medicine: https://www.nejm.org/doi/full/10.1056/NEJMoa2211582. Our Guest:Dr. Jennifer Brown is the Director of the CLL Center of the Division of Hematologic Malignancies at Dana-Farber Cancer Institute and Professor of Medicine in the Field of Hematologic Oncology at Harvard Medical School in Boston, Massachusetts.This podcast episode was sponsored by BeiGene Canada ULC.If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com
Embed this episode
What this episode covers
Live From ASH, New Orleans: In this episode, Dr. Jennifer Brown discusses results of the phase 3 ALPINE trial, presented as a late breaking abstract at the American Society of Hematology (ASH) meeting 2022 in New Orleans, LA. Note: The ALPINE trial was published today in the New England Journal of Medicine: https://www.nejm.org/doi/full/10.1056/NEJMoa2211582. Our Guest: Dr. Jennifer Brown is the Director of the CLL Center of the Division of Hematologic Malignancies at Dana-Farber Cancer ...
NOW PLAYING
ASH Highlights - ALPINE Trial Shows Improved Efficacy and Safety Profile of Zanubrutinib vs Ibrutinib in CLL
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.